Features
Pricing
Newsletter
Events
Partners
Features
Pricing
Newsletter
Events
Partners
Loading organizations...
Asahi Kasei Pharma: Funding, Team & Investors | Startup Intros
Home
/
Organizations
/
Asahi Kasei Pharma
Asahi Kasei Pharma
Active
Website
LinkedIn
Follow
Copy .md
Share
Post on X
Post on LinkedIn
Share on Reddit
Share on WhatsApp
Share on Telegram
Send an Email
Updated:
Apr 1, 2026
·
Suggest an edit
About
News
Financials
Team
Deep Dive
FAQs
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Asahi Kasei Pharma.
DE
Dalton Einhorn
Director New Pharma Ventures
Leadership Team
Key people at Asahi Kasei Pharma.
Dalton Einhorn
Director New Pharma Ventures
Financial History
Total Raised
N/A
Valuation
N/A
Investments Made
Date
Company
Round
Lead Investor(s)
Co-Investor(s)
Jan 7, 2026
Mediar Therapeutics
$76.0M Series B
Allan Marchington
, Bharat Srinivasa
Alexandria Venture Investments
,
Longwood Fund
Mar 22, 2023
Curreio
$2.0M Series A
—
3S Capital
, Takehiko Sawabe
,
DOJIN Capital
,
IKERUNippon Capital Partners
,
Ono Venture Investment
, Kamada
,
U-Tokyo Entrepreneur Supporter
Dec 1, 2022
Pulmocide
$52.0M Series C
—
Adjuvant Capital
,
Cystic Fibrosis Foundation
, F-Prime Capital
, Sabine Dandiguian
, Johnson & Johnson Innovation
,
Longwood Fund
,
Pictet Alternative Advisors
,
SR One
, SV Health Investors
,
Vivo Capital
Jun 1, 2022
LUCA Science
$29.0M Series B
4BIO Capital
, Shuntaro Kodama
Astellas Venture Management
,
Axil Capital
,
Mogrify
,
Parkwalk Advisors
,
Remiges Ventures
,
Sana Capital
, Jonathan Milner
,
Nippon Venture Capital
,
Nissay Capital
,
QB Capital/NCB Venture Capital
,
SMBC Venture Capital
May 1, 2021
Pulmocide
$92.0M Series C
Sabine Dandiguian
Adjuvant Capital
, F-Prime Capital
, Johnson & Johnson Innovation
,
Longwood Fund
,
SR One
, SV Health Investors